BC Cancer Hazardous Drug List

The BC Cancer Hazardous Drug List will be made available in each BC Cancer Regional Centre Pharmacy. See BC Cancer Provincial Pharmacy Directive VI-80 *Hazardous Drug List* (currently under revision) for details regarding the evaluation process for hazardous drugs. For questions pertaining to safe handling of hazardous drugs, see BC Cancer Provincial Pharmacy Directive VI-40 *Safe Handling and Preparation of Hazardous Drug Dosage Forms* (currently under revision) and/or the BC Cancer Safe Handling Standards Manual.

The BC Cancer Hazardous Drug List (BC Cancer HD List) is comprised of:

- **BC Health Authorities Provincial Hazardous Drug List** as approved by the Provincial Pharmacy Hazardous Drug Review Committee. See BC Provincial Hazardous Drug List at BC Hazardous Drugs Safety. (Please note the link to the BC Provincial Hazardous Drug List is accessible to BC Health Authorities only.)

  AND

- **BC Cancer Addendum** (see below), which includes additional hazardous drugs evaluated by BC Cancer.

User Guide: see next page for more information.

BC Cancer Addendum to the BC Hazardous Drug List

NEW - SAP	
vorasidenib	Group 2

intentionally blank	

intentionally blank	

User Guide for Table:

Definitions:

- **Hazardous Drug** (HD): all drugs found on the BC Cancer HD List have met one or more of the NIOSH criteria for an HD and exhibits at least one of the following characteristics in animals or humans:

    1. carcinogenicity
    2. teratogenicity or other developmental toxicity
    3. reproductive toxicity
    4. organ toxicity at low doses
    5. genotoxicity

    OR the drug**:**

    1. has a structure and toxicity profile that mimics an existing drug previously determined hazardous by the above criteria (e.g., pegylated liposomal doxorubicin, paclitaxel NAB, etc.)
    2. is or contains a living organism with the potential to cause infections in humans
    3. has insufficient information to properly evaluate the characteristics of the drug (e.g., investigational drug, drug only available via Health Canada Special Access program, etc.) but the drug is primarily used to treat cancer

- **Hazardous Drug <u>Group 1</u>**: A drug will be classified HD Group 1 on the BC Cancer HD List if:

    1. It is included on the current NIOSH List in Table 1
    2. It is evaluated by the Provincial Pharmacy HD Review Committee or BC Cancer as hazardous and meets one or more of the following criteria for a hazardous drug:
        i. meets the NIOSH criteria for carcinogenicity animals or humans
        ii. meets the NIOSH criteria for genotoxicity/mutagenicity animals or humans
        iii. has Manufacturer's Safe Handling Information (MSHI) in the product information
        iv. is classified by the National Toxicology Program (NTP) as "known to be a human carcinogen"
        v. is classified by the International Agency for Research on Cancer (IARC) as "carcinogenic" or "probably carcinogenic"
        vi. is evaluated as "cytotoxic" or is described as having a "cytotoxic mechanism of action" by the Provincial Pharmacy Hazardous Drug Review Committee per the Guiding Principles for the BC Hazardous Drug List
        vii. drug contains a living organism with the potential to cause infection in humans (i.e., biohazardous)
        viii. is a new drug with a structure and toxicity profile that mimics an existing drug previously determined to be a HD Group 1 by the previous criteria

- **Hazardous Drug <u>Group 2</u>**: A drug will be classified as HD Group 2 on the BC Cancer HD List if:
    1. It is included on the current NIOSH List in Table 2
    2. It is evaluated by the Provincial Pharmacy HD Review Committee or BC Cancer and does NOT meet one of the criteria for a Group 1 drug, but does meet one or more of the following criteria:
        i. meets the NIOSH criteria for teratogenicity/developmental toxicity animals or humans
        ii. meets the NIOSH criteria for reproductive toxicity animals or humans
        iii. meets the NIOSH criteria for low dose organ toxicity animals or humans
        iv. is a new drug with a structure and toxicity profile that mimics an existing drug previously determined to be a HD Group 2 by the previous criteria
    3. There is insufficient information to properly evaluate the characteristics of the drug (e.g., investigational drug, drug only available via Health Canada Special Access program, etc.) but the drug is primarily used to treat cancer